ogdh-1 Antibody

What is OGDH and why is it an important protein target for antibody-based research?

OGDH (oxoglutarate dehydrogenase) is a critical enzyme in cellular metabolism, functioning as the E1 component of the 2-oxoglutarate dehydrogenase complex (OGDHC). This enzyme catalyzes the irreversible decarboxylation of 2-oxoglutarate (alpha-ketoglutarate) via thiamine diphosphate (ThDP) cofactor and subsequent transfer of the decarboxylated acyl intermediate to the E2 enzyme. OGDH plays a key role in the Krebs (citric acid) cycle, which is essential for the oxidation of fuel molecules including carbohydrates, fatty acids, and amino acids. The protein has a molecular weight of approximately 115.9 kilodaltons and is also known by alternative names including AKGDH, OGDC, and E1k . Recent research has also linked OGDH to neurodevelopmental disorders, making it an important target for studies in both metabolic and neurological research contexts .

How do I select the most appropriate OGDH antibody for my specific research application?

When selecting an OGDH antibody for research, consider these critical factors: (1) Validated applications - verify the antibody has been tested for your specific application (WB, IHC, ICC/IF, ELISA, Flow Cytometry); (2) Species cross-reactivity - ensure compatibility with your experimental model (human, mouse, rat, etc.); (3) Epitope recognition - antibodies targeting different regions (N-terminal, C-terminal) may perform differently; (4) Clonality - polyclonal antibodies offer broader epitope recognition while monoclonal antibodies provide higher specificity; (5) Citation record - previously published research using the antibody validates its performance. For instance, some OGDH antibodies like GeneTex's C-terminal antibody are validated for WB, IHC-p, ICC, and IF applications with human and mouse reactivity, while others like Aviva Systems Biology's N-terminal antibody shows broader species reactivity including human, mouse, rabbit, rat, bovine, guinea pig, and horse . Always request data sheets and validation information from suppliers before finalizing your selection.

What are the most effective techniques for optimizing OGDH antibody performance in Western blot applications?

Optimizing OGDH antibody performance in Western blot applications requires a systematic approach addressing multiple parameters. First, sample preparation is critical—OGDH is primarily a mitochondrial protein (with some nuclear localization), so ensure complete cell lysis with appropriate buffers containing protease inhibitors to prevent degradation . For protein extraction, RIPA buffer has been successfully used in research contexts . Given OGDH's large size (approximately 115.9 kDa), use lower percentage (7-10%) SDS-PAGE gels for better resolution and longer transfer times (potentially overnight at lower voltage) to ensure complete transfer of this high molecular weight protein . For primary antibody incubation, start with manufacturer-recommended dilutions (typically 1/500-1/1000) , but be prepared to optimize through titration experiments. Consider using milk-based blocking buffers, as BSA may increase background with some antibodies. Extended washing steps (at least 3×10 minutes) are particularly important for reducing background. For detection, both chemiluminescence and fluorescence-based methods have been successful, though the former may offer better sensitivity for lower-abundance samples. Finally, always include a positive control lysate from cells known to express OGDH and validate observed band size against the expected molecular weight (observed at approximately 110 kDa in some experiments) .

How can I troubleshoot non-specific binding or weak signals when using OGDH antibodies in immunohistochemistry?

When troubleshooting non-specific binding or weak signals in OGDH immunohistochemistry, first examine your antigen retrieval method. OGDH, as a mitochondrial protein, may require more aggressive antigen retrieval methods such as high-temperature citrate buffer or EDTA treatment to expose epitopes effectively. For non-specific binding issues, increase blocking time (2-3 hours) and concentration (5-10% normal serum corresponding to secondary antibody species), and consider adding 0.1-0.3% Triton X-100 to reduce hydrophobic interactions. If background persists, use more dilute antibody concentrations than the recommended 1/50-1/200 range and extend washing steps between incubations. For weak signal issues, verify tissue fixation conditions—overfixation can mask epitopes while underfixation can degrade the target protein. Consider signal amplification systems such as polymer-based detection or tyramide signal amplification if the protein is expressed at low levels. Antibody selection is crucial—C-terminal directed antibodies like ab137773 have shown good IHC-P performance in published studies . Always run parallel positive controls (tissues known to express OGDH) and negative controls (primary antibody omission and isotype controls) to validate staining specificity. If problems persist, consider testing alternative antibody clones, as epitope accessibility can vary substantially in fixed tissues.

What are the key considerations for quantifying OGDH protein levels in cell and tissue samples?

Accurate quantification of OGDH protein levels requires attention to several critical factors throughout the experimental workflow. Sample preparation methods should be standardized across experimental groups, with particular attention to subcellular fractionation techniques when comparing mitochondrial versus nuclear OGDH populations . For Western blot quantification, use appropriate loading controls—housekeeping proteins like GAPDH for total cell lysates or TOM20 for mitochondrial fractions as demonstrated in published protocols . Densitometric analysis should include linear standard curves using recombinant OGDH or serial dilutions of a reference sample to ensure measurements fall within the linear range of detection. For immunofluorescence quantification, Z-stack imaging and deconvolution may be necessary to accurately capture the three-dimensional distribution of OGDH within mitochondrial networks. When comparing protein levels between experimental conditions, normalization strategies should account for potential changes in mitochondrial content or cell size. Protein degradation can significantly impact results, as demonstrated in studies using cycloheximide treatment to examine OGDH stability . Methods like qPCR can complement protein measurements to distinguish between transcriptional and post-transcriptional regulatory mechanisms affecting OGDH levels. Finally, statistical analysis should account for the typically log-normal distribution of protein expression data, with appropriate tests such as the Wilcoxon test used in published OGDH studies .

How can OGDH antibodies be used to investigate the dual localization of OGDH in mitochondria and nucleus?

Investigating the dual localization of OGDH in mitochondria and nucleus requires sophisticated immunolabeling and imaging techniques. Begin with subcellular fractionation to biochemically separate mitochondrial and nuclear compartments, followed by Western blot analysis using purified OGDH antibodies alongside compartment-specific markers (e.g., VDAC or TOM20 for mitochondria; Lamin B1 or Histone H3 for nucleus). For microscopy approaches, implement super-resolution techniques such as structured illumination microscopy (SIM) or stimulated emission depletion (STED) microscopy to achieve the spatial resolution necessary to distinguish genuine nuclear OGDH from mitochondria adjacent to or wrapped around the nucleus. Co-immunostaining with KAT2A is particularly valuable as research has shown that nuclear OGDH associates with this protein on chromatin to provide succinyl-CoA for histone succinyltransferase activity . For live-cell imaging, consider using split-GFP complementation systems with OGDH fused to one fragment and compartment-specific proteins fused to the complementary fragment. Proximity ligation assays (PLA) can confirm interactions between OGDH and nuclear proteins in situ. When performing these experiments, account for potential cell-type differences in nuclear OGDH distribution and consider examining dynamic changes in localization under different metabolic conditions or cell cycle stages, as the nuclear fraction of OGDH has been implicated in epigenetic regulation through histone modifications .

What strategies can be employed to study OGDH complex formation and interaction dynamics using antibody-based approaches?

Studying OGDH complex formation and interaction dynamics requires multifaceted antibody-based approaches that capture both stable complexes and transient interactions. Co-immunoprecipitation (Co-IP) experiments using OGDH antibodies can isolate the entire 2-oxoglutarate dehydrogenase complex, allowing identification of the E2 (dihydrolipoyllysine-residue succinyltransferase or DLST) and E3 (dihydrolipoyl dehydrogenase) components as well as regulatory binding partners . For more sensitive detection of interactions, proximity-dependent labeling methods such as BioID or APEX2 with OGDH fusion proteins complement traditional antibody approaches by identifying proteins within nanometer-scale proximity in living cells. To examine dynamics, pulse-chase experiments combined with immunoprecipitation can track complex assembly rates. For spatial organization studies within mitochondria, structured illumination microscopy with dual immunolabeling of OGDH and other complex components provides nanoscale resolution of colocalization patterns. Native-PAGE followed by immunoblotting preserves intact complexes better than denaturing SDS-PAGE. Cross-linking mass spectrometry (XL-MS) approaches, where protein complexes are chemically cross-linked before immunoprecipitation with OGDH antibodies, can map actual interfaces between OGDH and its binding partners. When investigating nuclear OGDH complexes specifically, chromatin immunoprecipitation (ChIP) using OGDH antibodies followed by sequencing can identify genomic regions where OGDH-containing complexes associate with DNA, providing insight into its role in epigenetic regulation through interaction with histone succinyltransferase KAT2A .

How can OGDH antibodies be utilized to investigate the role of this protein in neurodevelopmental disorders?

Investigating OGDH's role in neurodevelopmental disorders requires specialized antibody applications that bridge molecular mechanisms with disease phenotypes. Patient-derived cells (fibroblasts, lymphoblasts, or iPSC-derived neurons) provide valuable models where OGDH antibodies can assess protein abundance, localization, and post-translational modifications in disease contexts . Immunohistochemistry on post-mortem brain tissues using validated OGDH antibodies can reveal altered expression patterns or mislocalization in affected neural circuits. For functional studies, combine OGDH antibodies with metabolic measurements—immunoprecipitation followed by activity assays can determine if pathogenic variants affect enzymatic function, while JC-1 or TMRM staining coupled with OGDH immunofluorescence can correlate protein levels with mitochondrial membrane potential at the single-cell level. In animal models, stereotactic injection of OGDH antibodies conjugated to cell-penetrating peptides can acutely disrupt protein function in specific brain regions to evaluate behavioral consequences. For developmental studies, immunohistochemistry across embryonic and postnatal time points can track OGDH expression during critical neurodevelopmental windows. Recent research has identified biallelic variants in OGDH associated with disorders characterized by global developmental delay, movement disorders, and metabolic abnormalities . When examining such variants, immunoblotting can assess protein stability (as demonstrated in studies using cycloheximide treatment), while immunofluorescence can reveal altered subcellular distribution that might disrupt energy metabolism in neurons with high energetic demands, potentially explaining the neurological phenotypes observed in affected individuals.

What are the essential validation steps for confirming OGDH antibody specificity and reliability?

Comprehensive validation of OGDH antibody specificity requires a strategic multi-method approach. Begin with genetic knockout/knockdown controls—compare antibody signals in wild-type cells versus those with CRISPR/Cas9-mediated OGDH knockout or siRNA knockdown. The complete disappearance or significant reduction of signal provides strong evidence for specificity. Pre-absorption tests, where the antibody is pre-incubated with excess recombinant OGDH protein before application to samples, should eliminate specific signals while leaving non-specific background intact. Multi-antibody validation comparing staining patterns from different antibodies targeting distinct OGDH epitopes can confirm true signals when patterns converge. For recombinant expression validation, compare detection of overexpressed OGDH-FLAG constructs (wild-type and variants) with both anti-OGDH and anti-FLAG antibodies to verify concordant signals, as demonstrated in published research . Mass spectrometry validation of immunoprecipitated proteins provides orthogonal confirmation of antibody target engagement. Run Western blots under reducing and non-reducing conditions to verify that the antibody recognizes the denatured epitope at the expected molecular weight (approximately 110-116 kDa) . Cross-reactivity testing against related family members, particularly OGDHL (OGDH-like), is essential due to sequence homology. Finally, include application-specific controls—for example, in subcellular localization studies, co-stain with established mitochondrial and nuclear markers to confirm the reported dual localization of OGDH in these compartments .

How should researchers interpret and troubleshoot discrepancies in OGDH antibody results across different experimental platforms?

When encountering discrepancies in OGDH antibody results across different experimental platforms, researchers should implement a systematic troubleshooting approach. First, examine epitope accessibility differences—the 115.9 kDa OGDH protein may present epitopes differently in native (immunoprecipitation, flow cytometry) versus denatured (Western blot) conditions, particularly for conformation-sensitive antibodies . Post-translational modifications can mask epitopes in tissue-specific or condition-dependent manners; phosphoproteomics or other modification-specific analyses may reveal whether this contributes to discrepancies. Fixation-induced epitope alterations are particularly relevant when comparing fresh-frozen versus formalin-fixed paraffin-embedded tissues—C-terminal directed antibodies like ab137773 may perform differently than N-terminal antibodies across these platforms . Cross-reactivity with OGDH-like proteins or splice variants should be investigated through isoform-specific knockdown experiments. Buffer composition significantly impacts results—detergent types and concentrations appropriate for the mitochondrial localization of OGDH should be optimized for each application. For quantitative discrepancies, examine detection method linear ranges—chemiluminescence, fluorescence, and colorimetric methods have different dynamic ranges and sensitivity limits. When troubleshooting immunohistochemistry versus Western blot discrepancies, remember that IHC provides spatial information but is more susceptible to fixation artifacts, while Western blotting confirms molecular weight but loses spatial context. Finally, consider biological variability—OGDH's dual localization in mitochondria and nucleus means that experimental manipulations affecting mitochondrial dynamics or nuclear transport could produce apparently conflicting results across platforms that differentially preserve these compartments .

What strategies can be employed to develop and validate phospho-specific OGDH antibodies for studying post-translational regulation?

Developing phospho-specific OGDH antibodies requires precise targeting of known or predicted phosphorylation sites based on phosphoproteomic data. Begin by synthesizing phosphopeptides corresponding to these sites, ensuring they include 10-15 amino acids surrounding the phosphorylated residue and are conjugated to carrier proteins like KLH. Immunize rabbits using a prime-boost strategy with the phosphopeptide, followed by dual-affinity purification—first isolate total IgG, then perform positive selection using phosphopeptide-conjugated columns and negative selection with non-phosphorylated peptide columns to remove antibodies recognizing the non-phosphorylated epitope. Validation should include ELISA testing demonstrating at least 100-fold selectivity for phosphorylated versus non-phosphorylated peptides. For cellular validation, treat samples with phosphatases (e.g., lambda phosphatase) to demonstrate signal loss, and use pharmacological modulators of relevant kinase pathways to show dynamic regulation of the phospho-signal. Western blot validation should include phosphomimetic (S/T to D/E) and phosphodeficient (S/T to A) OGDH mutants expressed in cells, expecting signal from phosphomimetics but not phosphodeficient variants. Knockout/knockdown controls remain essential, as with standard antibodies . For functional validation, pair phospho-antibody detection with activity assays of the OGDH complex to correlate phosphorylation status with enzymatic function. Immunoprecipitation with phospho-specific antibodies followed by mass spectrometry can confirm target engagement and identify co-regulated proteins within the complex. Finally, for research applications, use these antibodies to investigate how OGDH phosphorylation changes during metabolic stress, mitochondrial dysfunction, or in disease models where the TCA cycle is dysregulated, providing insight into the post-translational regulation of this key metabolic enzyme.

How can OGDH antibodies contribute to understanding the role of metabolic dysfunction in neurodegenerative diseases?

OGDH antibodies provide powerful tools for investigating the intersection of metabolic dysfunction and neurodegeneration. In brain tissue analyses, multiplex immunofluorescence combining OGDH antibodies with markers of oxidative stress, mitochondrial dynamics, and cell-type specificity can reveal which neuronal populations show altered OGDH expression or localization in diseases like Alzheimer's, Parkinson's, or ALS. Recent research has established direct connections between OGDH mutations and neurodevelopmental disorders characterized by global developmental delay, movement disorders, and metabolic abnormalities . Antibody-based proximity ligation assays can detect interactions between OGDH and disease-associated proteins such as α-synuclein or tau, potentially uncovering novel mechanisms linking metabolic stress to protein aggregation. In cerebrospinal fluid biomarker studies, antibody-based assays measuring released OGDH following neuronal damage could serve as indicators of mitochondrial dysfunction. For mechanistic studies, co-immunoprecipitation using OGDH antibodies can identify altered protein interactions in disease models, while chromatin immunoprecipitation can assess changes in nuclear OGDH distribution that might affect epigenetic regulation through histone succinyltransferase activity . Importantly, comparative analysis of OGDH expression, post-translational modifications, and activity across brain regions with differential vulnerability to neurodegeneration may reveal metabolic signatures that explain selective neuronal loss. These approaches are particularly valuable given OGDH's position at the crossroads of the TCA cycle and amino acid metabolism, pathways increasingly recognized as dysregulated in multiple neurodegenerative conditions.

What methodological approaches enable the study of OGDH variants associated with human disease using antibody-based techniques?

Studying OGDH variants associated with human disease requires specialized antibody-based methodological approaches that integrate genetic, biochemical, and cellular analyses. For expression analysis, Western blotting with validated OGDH antibodies on patient-derived cells or tissues can determine if variants affect protein stability or steady-state levels, as demonstrated in studies using cycloheximide chase assays to examine protein degradation rates . Immunofluorescence microscopy comparing wild-type and variant OGDH localization can reveal mislocalization phenotypes that disrupt either mitochondrial or nuclear functions. For functional studies, activity-based probes combined with OGDH immunoprecipitation can assess how variants impact enzymatic function without requiring protein purification. Structure-function relationships can be explored through limited proteolysis followed by epitope-specific antibody detection to examine conformational changes induced by disease variants. For interaction studies, proximity ligation assays comparing wild-type and variant OGDH interactions with complex components (DLST, DLD) or regulatory partners can identify disrupted protein-protein interfaces. In cellular models, rescue experiments introducing wild-type OGDH-FLAG constructs into patient cells, followed by antibody detection of both endogenous and exogenous proteins, can confirm pathogenicity. For in vivo studies in model organisms, tissue-specific immunohistochemistry can correlate OGDH variant expression with histopathological and behavioral phenotypes. These approaches have already yielded insights into how biallelic OGDH variants cause neurodevelopmental disorders characterized by developmental delay, movement disorders, and metabolic abnormalities , illustrating the value of antibody-based techniques in translational research connecting genetic findings to disease mechanisms.

How can OGDH antibodies be utilized in high-throughput screening for compounds that modulate mitochondrial function?

Implementing OGDH antibodies in high-throughput screening for mitochondrial modulators requires innovative assay development that balances throughput with mechanistic insight. Cell-based immunofluorescence assays in 384- or 1536-well formats using automated imaging systems can quantify changes in OGDH abundance, localization, or post-translational modifications following compound treatment. By co-staining with mitochondrial morphology markers (e.g., MitoTracker) and OGDH antibodies, multidimensional phenotypic profiles can be generated that distinguish compounds affecting OGDH specifically versus general mitochondrial disruptors. For higher specificity, develop AlphaLISA or TR-FRET assays using donor-labeled OGDH antibodies and acceptor-labeled antibodies against interaction partners or post-translational modifications, enabling homogeneous detection of compound effects on OGDH interactions or regulation. Cell-based reporter systems where OGDH function is coupled to luciferase expression, validated by parallel immunoblotting with OGDH antibodies, provide a higher-throughput complement to direct antibody measurements. For mechanistic classification of hits, develop secondary assays measuring nuclear translocation of OGDH using cellular fractionation followed by immunoblotting to identify compounds specifically affecting the recently discovered nuclear functions of OGDH in histone modification . In advanced implementations, microfluidic immunoassays can enable real-time measurement of OGDH complex dynamics following compound addition. These approaches collectively create a screening platform that can identify compounds affecting OGDH stability, localization, complex formation, or activity, potentially yielding therapeutic candidates for diseases characterized by mitochondrial dysfunction, including the recently characterized neurodevelopmental disorders associated with OGDH variants .

How can OGDH antibodies be integrated with single-cell technologies to understand metabolic heterogeneity in complex tissues?

Integrating OGDH antibodies with single-cell technologies creates powerful approaches for mapping metabolic heterogeneity at unprecedented resolution. Mass cytometry (CyTOF) using metal-conjugated OGDH antibodies alongside lineage markers and other metabolic enzymes can quantify OGDH levels across thousands of individual cells while preserving tissue context information. This approach is particularly valuable in heterogeneous tissues like brain, where neurons, astrocytes, and oligodendrocytes may exhibit distinct OGDH expression patterns related to their metabolic profiles. For spatial information at single-cell resolution, multiplexed ion beam imaging (MIBI) or imaging mass cytometry with OGDH antibodies can map protein expression across tissue sections while preserving architectural information. Single-cell Western blotting using microfluidic platforms combined with OGDH antibody detection offers protein-level validation of expression heterogeneity with reduced antibody cross-reactivity concerns. For functional correlation, plate-based single-cell metabolomic profiling followed by fixation and OGDH immunostaining enables direct linking of metabolite levels to enzyme abundance in the same cells. In more sophisticated approaches, proximity ligation assays targeting OGDH interactions with different metabolic enzymes at the single-cell level can reveal functional metabolic modules that vary across cell types. These methodologies are particularly relevant for investigating diseases with cell-type specific vulnerabilities, such as the neurodevelopmental disorders associated with OGDH variants , where understanding which specific neural populations are most affected by altered OGDH function could explain selective symptomatology and identify targeted therapeutic approaches.

What are the current limitations of OGDH antibodies and what technological developments might overcome these challenges?

Current OGDH antibody limitations span specificity, sensitivity, and application versatility challenges that constrain research capabilities. Cross-reactivity with the paralog OGDHL (OGDH-like) remains problematic for many commercial antibodies, as both proteins share significant sequence homology. Most current antibodies cannot distinguish between mitochondrial and nuclear OGDH populations without subcellular fractionation, limiting studies of this protein's compartment-specific functions. Post-translational modification-specific antibodies (phospho, acetyl, succinyl) for OGDH are largely unavailable, despite the likely importance of these modifications in regulating this metabolic enzyme. For quantitative applications, the dynamic range of detection remains limited, particularly in tissues with low OGDH expression. Emerging technologies offer solutions to these challenges: recombinant antibody engineering using phage display with stringent negative selection against OGDHL could yield truly OGDH-specific binders. Nanobodies derived from camelid immunization may access epitopes poorly recognized by conventional antibodies due to their smaller size and unique complementarity-determining regions. Proximity-dependent labeling approaches using OGDH-BioID or APEX2 fusions followed by detection with anti-biotin or streptavidin could overcome sensitivity limitations. For distinguishing subcellular pools, developing conformation-specific antibodies that recognize distinct structural states of OGDH in different compartments represents a promising direction. Advances in spatial proteomics using antibody-oligonucleotide conjugates for highly multiplexed imaging could enable simultaneous detection of OGDH alongside dozens of interaction partners and metabolic enzymes. Finally, antibody fragments coupled to environment-sensitive fluorophores could create sensors that report not just on OGDH presence but also on its conformational state or activity in living cells.

How might advances in proteomics and structural biology inform the development of next-generation OGDH antibodies with enhanced specificity and functionality?

Advances in proteomics and structural biology are poised to revolutionize OGDH antibody development through epitope-guided antibody engineering. High-resolution cryo-electron microscopy structures of the complete OGDHC complex would reveal surface-accessible epitopes unique to OGDH that could be targeted for maximum specificity, particularly for distinguishing it from the paralogous OGDHL protein. Cross-linking mass spectrometry (XL-MS) studies mapping the OGDH interactome would identify regions that undergo conformational changes upon complex formation or enzymatic activity, enabling the design of conformation-specific antibodies that report on functional states rather than merely protein presence. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) could identify regions with differential solvent accessibility between mitochondrial and nuclear OGDH populations , informing development of compartment-specific antibodies. Deep mutational scanning coupled with antibody binding assays would map the contribution of each residue to epitope recognition, allowing rational engineering of antibodies with precise specificity profiles. For detecting disease-relevant variants, structural information about how mutations like p.(Pro189Leu), p.(Ser297Tyr), and p.(Arg312Lys) affect protein conformation could guide development of variant-specific antibodies that selectively recognize mutant but not wild-type protein. Advanced proteomic approaches identifying cell type-specific post-translational modifications of OGDH would enable development of modification-state specific antibodies that report on regulatory status. Computational antibody design leveraging these structural and proteomic datasets, combined with directed evolution platforms like yeast or phage display, could yield antibodies with programmable properties such as pH-dependent binding for selective detection in specific subcellular compartments. These technology-driven approaches would transform OGDH antibodies from simple detection reagents to sophisticated sensors of protein function, localization, and regulation.